A Study of CS1003 in Subjects With Advanced Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
This is a multi-center, double-blind, randomized, phase III study to investigate the efficacy
and safety of CS1003 in combination with lenvatinib and placebo in combination with
lenvatinib in the treatment of subjects with no prior systemic treatment and with
unresectable advanced hepatocellular carcinoma (HCC). Subjects cannot be eligible for
locoregional therapy. In this study, CS1003 (or placebo) and lenvatinib are both considered
as the study treatment while CS1003 (or placebo) is the investigational product of and
lenvatinib is selected as the basic treatment for HCC.